estimated revenue glp-1 drugs The United States Agonists Weight Loss Market Size & Outlook, 2030 Beyond GLP-1Rs: emerging targets poised
Description
Nothing is cookie-cutter
Annu Rev Med 2023;74:12539
Nutrition, exercise, sleep hygiene, stress management, and behavioural support are all essential
All groups reported the highest incidence of GI events early (within the first 2 weeks) in treatment
The difference between Exendin-4 and Exenatide lies primarily in the replacement of Ala with Valine (Val) at the 19th position and Asn with aspartic acid at the 28th position in Exendin-4
Long-term outcome data, particularly on cardiovascular events, is currently stronger for injectable semaglutide thanks to the SELECT trial
